Questions? Call Us: 707-622-5628

COVID-19 Updates

CALL TO ALL CARE SETTINGS: 9/17/2020 from 2 PM to 3 PM ET-Testing and Treatment of 2020-2021 Seasonal Influenza During the COVID-19 Pandemic

Testing and Treatment of 2020-2021 Seasonal Influenza During the 

COVID-19 Pandemic

You may participate in this COCA Call via Zoom

Overview

Influenza surveillance data reported to the World Health Organization’s FluNet platform from three Southern Hemisphere countries (Australia, Chile, and South Africa) indicated low influenza activity during June through August 2020, months that comprise the typical Southern Hemisphere influenza season. The low influenza activity observed in the Southern Hemisphere might reflect the impact of non-pharmaceutical interventions implemented to reduce the spread of SARS-CoV-2, the virus that causes COVID-19. However, it is not possible to predict influenza activity or the severity of the upcoming influenza season in the United States with the potential for co-circulation of influenza viruses and SARS-CoV-2. While vaccination remains the best way to prevent influenza, antiviral medications are an essential adjunct to vaccination—especially for treating outpatients with suspected or confirmed influenza, in persons at high risk for influenza complications, in those with progressive disease, and hospitalized influenza patients. 

During this COCA call, clinicians will hear an overview of CDC’s recommendations for health care providers regarding influenza diagnostics and the use of antiviral medications for the 2020-2021 influenza season, including considerations during the ongoing COVID-19 pandemic.

If you are unable to attend the live COCA Call, the recording will be available for viewing on the COCA Call webpage a few hours after the live event ends.

Date: Thursday, September 17, 2020

Time: 2:00 pm – 3:00 pm (ET)

A few minutes before the webinar starts, please click on the Zoom link below to join: https://www.zoomgov.com/j/1604984692

Or iPhone one-tap:

US: +16692545252,,1604984692# or +16468287666,,1604984692# 

Or Telephone: Dial(for higher quality, dial a number based on your current location): US: +1 669 254 5252 or +1 646 828 7666

Webinar ID: 160 498 4692

International numbers available: https://www.zoomgov.com/u/acBPf2bnGs

The slide set will be available under “Call Materials” on the COCA Call webpage. 

Free Continuing Education (CE) will be offered for this COCA Call. 

Advanced registration is not required.

Activity-specific Objectives

At the conclusion of the session, the participant will be able to accomplish the following—
  1. Review influenza activity since the onset of the COVID-19 pandemic.
  2. Provide background on influenza tests and antivirals for influenza.
  3. Describe influenza testing guidance for patients with acute respiratory illness for the 2020-2021 season, including during community co-circulation of influenza viruses and SARS-CoV-2.
  4. Describe antiviral treatment recommendations for patients with suspected or confirmed influenza for the 2020-2021 season, including during community co-circulation of influenza viruses and SARS-CoV-2.

COCA Call Objectives

At the conclusion of the session, the participant will be able to accomplish the following—
  1. Cite background information on the topic covered during the presentation.
  2. Discuss CDC’s role in the topic covered during the presentation.
  3. Describe the topic’s implications for clinicians.
  4. Discuss concerns and/or issues related to preparedness for and/or response to urgent public health threats.
  5. Promote health improvement, wellness, and disease prevention in cooperation with patients, communities, at-risk populations, and other members of an interprofessional team of health care providers.

Presenters

Angela Campbell, MD, MPH, FIDSA, FPIDS

Medical Officer, Influenza Division

National Center for Immunization and Respiratory Diseases

Centers for Disease Control and Prevention

Timothy Uyeki, MD, MPH, MPP, CAPT, USPHS

Chief Medical Officer, Influenza Division

National Center for Immunization and Respiratory Diseases

Centers for Disease Control and Prevention 

Instructions for Obtaining Continuing Education 

To receive continuing education (CE) for WC2922-091720 – Clinician Outreach and Communication Activity (COCA) Calls/Webinars – Testing and Treatment of 2020-2021 Seasonal Influenza During the COVID-19 Pandemic, Thursday, September 17, 2020, please visit TCEO and follow these 9 Simple Steps by Monday, October 19, 2020.

To receive continuing education (CE) for WD2922-091720 – Clinician Outreach and Communication Activity (COCA) Calls/Webinars – Testing and Treatment of 2020-2021 Seasonal Influenza During the COVID-19 Pandemic, Thursday, September 17, 2020, (Web on Demand), please visit TCEO and follow these 9 Simple Steps by Thursday, October 20, 2022.

Accreditation Statement

CME: The Centers for Disease Control and Prevention is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.
The Centers for Disease Control and Prevention designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
CNE: The Centers for Disease Control and Prevention is accredited as a provider of Continuing Nursing Education by the American Nurses Credentialing Center’s Commission on Accreditation.
This activity provides 1.0 contact hour.
CEU: The Centers for Disease Control and Prevention is authorized by IACET to offer 0.1 CEU’s for this program.
CECH: Sponsored by the Centers for Disease Control and Prevention, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designated for Certified Health Education Specialists (CHES) and/or Master Certified Health Education Specialists (MCHES) to receive up to total 1.0 total Category I continuing education contact hours. Maximum advanced level continuing education contact hours available are 0. CDC provider number 091720.
CPE: The Centers for Disease Control and Prevention is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program is a designated event for pharmacists to receive) 0.1 CEUs in pharmacy education. The Universal Activity Number is JA4008229-0000-20-049-L04-P and enduring JA4008229-0000-20-050-H04-P course category.
This activity has been designated as Knowledge-Based.
Once credit is claimed, an unofficial statement of credit is immediately available on TCEOnline. Official credit will be uploaded within 60 days on the NABP/CPE Monitor.
For Certified Public Health Professionals (CPH)
The Centers for Disease Control and Prevention is a pre-approved provider of Certified in Public Health (CPH) recertification credits and is authorized to offer 1.0 CPH recertification credit for this program.
AAVSB/RACE: This program was reviewed and approved by the AAVSB RACE program for 1.0 hours of continuing education. Participants should be aware that some boards have limitations on the number of hours accepted in certain categories and/or restrictions on certain methods of delivery of continuing education. Please contact the AAVSB RACE program at race@aavsb.org if you have any comments/concerns regarding this program’s validity or relevancy to the veterinary profession.
DISCLOSURE: In compliance with continuing education requirements, CDC, our planners, our presenters, and their spouses/partners wish to disclose they have no financial interests or other relationships with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters.
Planners have reviewed content to ensure there is no bias.
The presentation will not include any discussion of the unlabeled use of a product or a product under investigational use, except Dr. Angela Campbell would like to disclose that she will discuss the off label use of antiviral medications for treatment of influenza.
CDC did not accept commercial support for this continuing education activity.

The Emergency Risk Communication Branch in the Division of Emergency Operations, Center for Preparedness and Response is responsible for the management of all COCA products.

For information about this update or other clinical issues, or to send your feedback, please contact us at coca@cdc.gov

Content composed with the instant Online HTML editor. Please purchase a HTMLg license to remove the promotional messages from the edited documents.